Entrada Therapeutics (TRDA) News Today $7.59 -0.26 (-3.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.59 0.00 (0.00%) As of 06/13/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to SellWall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.June 14 at 2:16 AM | marketbeat.comMillennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Millennium Management LLC lowered its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 88.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,527 shares of the company's stock after selling 98,416 shares during thJune 12 at 3:08 AM | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLCNuveen Asset Management LLC trimmed its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 32.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,506 shares of the company's stoJune 4, 2025 | marketbeat.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29, 2025 | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28, 2025 | globenewswire.comQ2 EPS Estimate for Entrada Therapeutics Raised by AnalystEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - HC Wainwright upped their Q2 2025 EPS estimates for Entrada Therapeutics in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.98) for the quartMay 24, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TRDA Q2 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2026 EPS estimates for Entrada Therapeutics in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju forecasts that the companyMay 23, 2025 | marketbeat.comNorthern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Northern Trust Corp lifted its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 28.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 318,177 shares of the company's stock afMay 23, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday.May 22, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Janus Henderson Group PLC increased its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,080,367 shares of the company's stoMay 17, 2025 | marketbeat.comMPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)MPM Asset Management LLC trimmed its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,381,062 shares of the compMay 16, 2025 | marketbeat.comQ2 EPS Forecast for Entrada Therapeutics Reduced by AnalystEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2025 earnings per share estimates for Entrada Therapeutics in a report released on Sunday, May 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will postMay 16, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP increased its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 127.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 217,006 shares of the company's stock after puMay 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Issues Earnings ResultsEntrada Therapeutics (NASDAQ:TRDA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.May 12, 2025 | marketbeat.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD trimmed its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,903,025 shares of the company's stockMay 2, 2025 | marketbeat.comEntrada Therapeutics (TRDA) to Release Quarterly Earnings on TuesdayEntrada Therapeutics (NASDAQ:TRDA) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-entrada-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 72,400 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Renaissance Technologies LLC increased its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 77.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 166,200 shares of the company's stocApril 27, 2025 | marketbeat.comVanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Vanguard Group Inc. grew its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 19.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,464,237 shares of the company's stock after purchasing an additApril 17, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company's stock after purchasing an additioApril 16, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 123.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,520 shares of the company's stApril 11, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for TRDA EarningsEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Entrada Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now expects that the company wilApril 5, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Monday.April 1, 2025 | marketbeat.comEntrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMDMarch 26, 2025 | nasdaq.comEntrada receives authorization in the UK to initiate ELEVATE-45-201 studyMarch 25, 2025 | markets.businessinsider.comEntrada Therapeutics gets approval to start trial of its DMD treatment in the UKMarch 24, 2025 | msn.comEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMarch 24, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Reduces Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Connor Clark & Lunn Investment Management Ltd. reduced its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,621 shares of the comMarch 20, 2025 | marketbeat.comEntrada Therapeutics (TRDA) Expected to Announce Earnings on WednesdayEntrada Therapeutics (NASDAQ:TRDA) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comAnalysts Set Expectations for TRDA Q4 EarningsEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at Roth Capital issued their Q4 2026 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Friday, February 28th. Roth Capital analyst B. Pachaiyappan expects thatMarch 3, 2025 | marketbeat.comWhat is William Blair's Estimate for TRDA Q1 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Entrada Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will earn ($0.73) per shaMarch 3, 2025 | marketbeat.comEntrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen NextMarch 3, 2025 | finance.yahoo.comEntrada Therapeutics price target lowered to $23 from $29 at Roth MKMMarch 1, 2025 | markets.businessinsider.comEntrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPSEntrada Therapeutics (NASDAQ:TRDA - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.February 28, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)February 28, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)February 28, 2025 | markets.businessinsider.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comEntrada Shares Climb After FDA Removes Hold on Muscular Dystrophy TreatmentFebruary 25, 2025 | marketwatch.comEntrada Therapeutics, Inc.: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44February 24, 2025 | finanznachrichten.deEntrada announces FDA removal of clinical hold on ENTR-601-44February 24, 2025 | markets.businessinsider.comEntrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKMFebruary 24, 2025 | markets.businessinsider.comEntrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44February 24, 2025 | globenewswire.comEntrada Therapeutics: Cash-Rich Innovator With Asymmetric UpsideFebruary 19, 2025 | seekingalpha.comEntrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | msn.comH.C. Wainwright maintains $20 target on Entrada Therapeutics stockFebruary 4, 2025 | msn.com Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Media Mentions By Week TRDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼1.020.87▲Average Medical News Sentiment TRDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼32▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) News Structure Therapeutics News Aurinia Pharmaceuticals News Wave Life Sciences News Niagen Bioscience News Mineralys Therapeutics News Arcus Biosciences News Spyre Therapeutics News Akebia Therapeutics News CureVac News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s worst nightmareThe President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRDA Stock Free TRDA Stock Alerts